The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb

Role of Bisphosphonates in Breast Cancer Therapy

(2019) Hadar Goldvaser et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Modelling of Protein Kinase Signaling Pathways in Melanoma and Other Cancers

(2019) Manfred Kunz et al.   Cancers

Bisphosphonate-Generated ATP-Analogs Inhibit Cell Signaling Pathways

(2018) Satish R. Malwal et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma

(2018) Qiang Zuo et al.   ONCOGENE

Anticancer Activity of Polyoxometalate-Bisphosphonate Complexes: Synthesis, Characterization, In Vitro and In Vivo Results

(2017) Amandine Boulmier et al.   INORGANIC CHEMISTRY

Targeted agents and immunotherapies: optimizing outcomes in melanoma

(2017) Jason J. Luke et al.   Nature Reviews Clinical Oncology

NRAS-mutant melanoma: current challenges and future prospect

(2017) Eva Muñoz-Couselo et al.   OncoTargets and Therapy

Investigating the utility of human melanoma cell lines as tumour models

(2017) Krista Marie Vincent et al.   Oncotarget

The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines

(2016) M. Fragni et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma

(2016) Romany A. N. Johnpulle et al.   Current Oncology Reports

Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma

(2016) Eun Ho Kim et al.   Oncotarget

Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression

(2016) Johanna Eriksson et al.   Oncotarget

Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells

(2015) Tamás Garay et al.   PLoS One

MAP kinase activity supported by BRAF V600E mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases

(2014) Peter Birner et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF

(2014) Ian R. Watson et al.   CANCER RESEARCH

Nras in melanoma: Targeting the undruggable target

(2014) Mario Mandalà et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Bisphosphonates inactivate human EGFRs to exert antitumor actions

(2014) Tony Yuen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin

(2014) Y. Xia et al.   Science Translational Medicine

Cell migration or cytokinesis and proliferation? – Revisiting the “go or grow” hypothesis in cancer cells in vitro

(2013) Tamás Garay et al.   EXPERIMENTAL CELL RESEARCH

Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells

(2013) H. Ding et al.   HAEMATOLOGICA

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

(2013) C. Posch et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway

(2012) Masanobu Tsubaki et al.   BIOCHEMICAL PHARMACOLOGY

Melanoma: New Insights and New Therapies

(2012) Vasiliki A. Nikolaou et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas

(2010) John T. Lee et al.   Pigment Cell & Melanoma Research

The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts

(2009) Angela C. Hirbe et al.   BONE

Lipophilic Bisphosphonates as Dual Farnesyl/Geranylgeranyl Diphosphate Synthase Inhibitors: An X-ray and NMR Investigation

(2009) Yonghui Zhang et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling

(2009) A B Hanker et al.   ONCOGENE

Biodistribution and Plasma Protein Binding of Zoledronic Acid

(2008) H. M. Weiss et al.   DRUG METABOLISM AND DISPOSITION